<?xml version="1.0" encoding="UTF-8"?>
<p>Principle behind use: RDV has been shown to have activity against varying coronaviruses in the airway epithelial cells in humans [
 <xref rid="REF12" ref-type="bibr">12</xref>]. Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT-1) suggest that a 10-day course of RDV was more effective than a placebo in the treatment of hospitalized patients with COVID-19. The benefit was seen in terms of shortened recovery time (11 days versus 15 days). On May 1, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for RDV for the treatment of adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19, which was later expanded to include all adult and pediatric patients hospitalized with suspected or laboratory-confirmed COVID-19, and for whom the use of an intravenous (IV) agent is clinically appropriate [
 <xref rid="REF16" ref-type="bibr">16</xref>]. 
</p>
